Stocks · News reference
Filed: 2026-11-06 AccNo: 0001193125-26-450716 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Tilray Brands maintains a 4x revenue advantage over Canopy Growth, consistently generating $200+ million quarterly revenue compared to Canopy's $45-73 million. While both companies show year-over-year growth when comparing comparable quarters, Tilray demonstrates more stable and higher revenue levels. Canopy's latest Q4 2025 quarter ($73.3M) suggests potential momentum, but the revenue gap remains substantial.
Tilray Brands stock has plummeted 70% in 2026 and 97% over five years despite generating nearly $1 billion in revenue. While the company has grown through acquisitions in beverages and alcohol, it remains unprofitable with an operating loss of $60.5 million over the trailing 12 months. The analyst argues the stock could fall further due to weak organic growth, continued cash burn, and limited profitability prospects, despite its low valuation of $400 million market cap.
President Trump's Executive Order to reschedule marijuana to Schedule III has stalled at the DEA due to bureaucratic delays and a temporary stay issued in September. While Canopy Growth shares initially surged on the news, they have since declined significantly. However, the article argues that U.S. rescheduling is a secondary concern for the Canada-based company, which faces more pressing operational challenges including persistent losses and dilutive equity financing.
The article compares two major cannabis companies navigating industry challenges. Canopy Growth focuses on premium Canadian cannabis and European medical sales but faces internal control weaknesses and significant losses. Tilray Brands has diversified into beverages and international markets, posting record Q1 revenue of $257M with improving margins. The author recommends Tilray as the better choice due to its larger scale, diversified revenue streams, and clearer path to profitability, though both stocks remain risky investments in a volatile industry.
Tilray Brands reported Q1 fiscal 2027 results with concerning fundamentals despite revenue growth. The company's cash burn spiked to $16.5 million (up from $1.3 million year-over-year), core cannabis revenue declined 13%, and operating expenses surged 83%. While top-line growth was driven by acquisitions like BrewDog, organic cannabis business weakness and ballooning costs suggest the stock faces continued headwinds.
Utah Medical Products (UTMD) trades at a premium valuation of 4.05X EV/sales versus industry average of 2.68X. While the company benefits from strong margins (58.2% gross margin), a debt-free balance sheet with $87.5M in cash, and strategic acquisitions, it faces near-term headwinds including 12.3% revenue decline, major customer losses, and projected 10-13% revenue decline for 2026. Long-term investors may hold, but new investors should await a better entry point.